Gaucher's disease

(redirected from Gaucher's)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to Gaucher's: Gaucher's cells

Gaucher's disease

 [go-shāz´]
a hereditary disorder of glucocerebroside metabolism, marked by the presence of Gaucher's cells in the bone marrow, and by hepatosplenomegaly and erosion of the cortices of long bones and pelvis. Type 1, the adult form, is associated with moderate anemia and thrombocytopenia, and yellowish pigmentation of the skin. Type 2, the infantile form, also has marked central nervous system impairment. In type 3, the juvenile form, there are rapidly progressive systemic manifestations but moderate central nervous system involvement.

Gaucher's disease

[gôshāz′]
Etymology: Phillipe C.E. Gaucher, French physician, 1854-1918
a rare autosomal-recessive familial disorder of lipid metabolism caused by an enzyme deficiency, characterized by widespread reticulum cell hyperplasia in the liver, spleen, lymph nodes, and bone marrow. Beginning in infancy or early childhood, splenomegaly, hepatomegaly, and abnormal bone growth develop. Diagnosis is made through biopsy of the liver, spleen, or bone marrow. Mortality rate is high, but children who survive adolescence may live for many years. Also called glucosyl cerebroside lipidosis.
enlarge picture
Bone marrow smear in Gaucher's disease

Gaucher's disease

A rare hereditary metabolic disease due to an enzyme defect that interferes with the proper function of cell LYSOSOMES. The condition features massive accumulation of materials called glucocerebrosides in the lysosomes. There is great enlargement of the liver and spleen, bone marrow displacement, bleeding tendency, bronzing of the skin, and anaemia. Also known as cerebroside lipidosis. (Philip Charles Ernst Gaucher, 1854–1918, French physician).

Gaucher's disease

A rare genetic disease caused by a deficiency of enzymes needed for the processing of fatty acids.
Mentioned in: Enzyme Therapy

Gaucher's disease

a hereditary disorder of glucocerebroside metabolism, marked by the presence of Gaucher's cells in many tissues. Occurs in dogs (Australian silky terriers), sheep, pigs and mice. See also glucocerebroside, gaucher's cells.
References in periodicals archive ?
AVAIL SAMPLE @ Gaucher's Disease - Pipeline Review, H2 2015
Companies involved in therapeutics development for Gaucher's Disease and discussed in this research include Amicus Therapeutics, Inc.
Gaucher's disease is the most common genetic disease among the Ashkenazi Jewish population of Eastern European ancestry.
Surgical management of spinal involvement in children and adolescents with Gaucher's disease.
2] Fortunately, considering the severity of the disease and the great expense of treatment, the number of patients afflicted is much more limited than the 2,000-3,000 individuals with Gaucher's Disease.
Previous attempts to treat Gaucher's disease with injections of the fully functioning enzyme failed because scientists couldn't get enough of the lifesaving substance into the patients' macrophages.
A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
studied 47 unrelated patients with Type I Gaucher's disease.
When the undegraded fat builds up, it can cause several types of Gaucher's disease.
Our clinical trial report, "Gaucher's Disease Global Clinical Trials Review, H2, 2012" provides data on the Gaucher's Disease clinical trial scenario.
Gaucher's barn on Norcross Road has been filled with cats.
Oxford GlycoSciences plc (LSE: OGS) today announced that OGT 918 (Vevesca(TM)) has been designated as an Orphan Medicinal Product by the European Commission for the treatment of Gaucher's Disease.